Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results.

Youlia M. Kirova,Delphine Loirat,Frédérique Berger,Manuel Rodrigues,L. Bazire,Jean-Yves Pierga,Francesco Ricci,Kim Cao,Anne Vincent-Salomon,Fatima Laki,Cyrine Ezzili,Laurence Raizonville,Véronique Mosseri,Souhir Neffati,Mounia Ezzalfani,Alain Fourquet

Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results.

2020

Youlia M. Kirova
Delphine Loirat
Frédérique Berger
Manuel Rodrigues
L. Bazire
Jean-Yves Pierga
Francesco Ricci
Kim Cao
Anne Vincent-Salomon
Fatima Laki
Cyrine Ezzili
Laurence Raizonville
Véronique Mosseri
Souhir Neffati
Mounia Ezzalfani
Alain Fourquet

571Background: Preclinical studies have shown that cell lines and murine models of TNBC phenotype are more sensitive to PARP1 inhibitors. This evidence provides strong rationale for developing a ne...

Keywords:

Olaparib
Oncology
Triple-negative breast cancer
in patient
Internal medicine
Pathology
PARP1
Radiation therapy
Medicine
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations